Given that HFpEF patients often have co-morbidities such as T2DM, the true effectiveness of GLP-1 agonists remains to be seen, and further investigation into the mechanisms underlying the diminished effect on SERCA is required. This evidence concerns the gene GCG and type 2 diabetes mellitus.